Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Flaherty

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsAdemi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, et al.
Cancer Medicine|December 4, 2025
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic MutationsDerek Effiom, Tyler Aprati, Anastasios Karneris, et al.
Nature Communications|November 16, 2019
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapiesJoan Montero, Cécile Gstalder, Daniel J Kim, et al.
The Oncologist|March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
The Journal of Investigative Dermatology|October 15, 2010
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cellsHeike Niessner, Daniela Beck, Tobias Sinnberg, et al.
Journal for Immunotherapy of Cancer|February 26, 2021
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohortXue Bai, Michelle Kim, Gyulnara Kasumova, et al.
The Lancet. Oncology|February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialReinhard Dummer, Jan C Brase, James Garrett, et al.
Cancer Journal (Sudbury, Mass.)|January 22, 2014
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United StatesLawrence Flaherty, Omid Hamid, Gerald Linette, et al.
Cancer Medicine|October 18, 2013
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Andrea Forschner, Bernhard Klumpp, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsAdemi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, et al.
Cancer Medicine|December 4, 2025
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic MutationsDerek Effiom, Tyler Aprati, Anastasios Karneris, et al.
Nature Communications|November 16, 2019
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapiesJoan Montero, Cécile Gstalder, Daniel J Kim, et al.
The Oncologist|March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
The Journal of Investigative Dermatology|October 15, 2010
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cellsHeike Niessner, Daniela Beck, Tobias Sinnberg, et al.
Journal for Immunotherapy of Cancer|February 26, 2021
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohortXue Bai, Michelle Kim, Gyulnara Kasumova, et al.
The Lancet. Oncology|February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialReinhard Dummer, Jan C Brase, James Garrett, et al.
Cancer Journal (Sudbury, Mass.)|January 22, 2014
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United StatesLawrence Flaherty, Omid Hamid, Gerald Linette, et al.
Cancer Medicine|October 18, 2013
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Andrea Forschner, Bernhard Klumpp, et al.
Pageof 7